stoxline Quote Chart Rank Option Currency Glossary
Orgenesis Inc. (ORGS)
0.7075  -0.032 (-4.31%)    07-18 15:50
Open: 0.73
High: 0.75
Volume: 42,758
Pre. Close: 0.739
Low: 0.7
Market Cap: 33(M)
Technical analysis
2024-07-18 3:22:17 PM
Short term     
Mid term     
Targets 6-month :  0.99 1-year :  1.15
Resists First :  0.84 Second :  0.99
Pivot price 0.66
Supports First :  0.6 Second :  0.44
MAs MA(5) :  0.71 MA(20) :  0.63
MA(100) :  0.61 MA(250) :  0.61
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  49.8 D(3) :  53
RSI RSI(14): 59.9
52-week High :  1.16 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ORGS ] has closed below upper band by 23.6%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.8 - 0.8 0.8 - 0.8
Low: 0.69 - 0.7 0.7 - 0.7
Close: 0.71 - 0.72 0.72 - 0.72
Company Description

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Headline News

Mon, 15 Apr 2024
Aristocrat Leisure market challenges lead to Netural stock rating from Goldman By -

Mon, 04 Mar 2024
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119% - Simply Wall St

Wed, 31 Jan 2024
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic - Yahoo Finance

Mon, 28 Aug 2023
Orgenesis Inc (ORGS): A Deep Dive into Its Performance Potential - Yahoo Finance

Tue, 11 Jul 2023
Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera - citybiz

Tue, 18 Jan 2022
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing - BioBuzz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 47 (M)
Held by Insiders 2.919e+007 (%)
Held by Institutions 29.3 (%)
Shares Short 249 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.017e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -6 %
Return on Assets (ttm) 333.3 %
Return on Equity (ttm) -41.9 %
Qtrly Rev. Growth 529000 %
Gross Profit (p.s.) -0.57
Sales Per Share -263.92
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -1.08
Stock Dividends
Dividend 0
Forward Dividend 194910
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android